Cwm LLC Has $298,000 Holdings in Perrigo Company plc (NYSE:PRGO)

Cwm LLC boosted its position in shares of Perrigo Company plc (NYSE:PRGO) by 38.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,380 shares of the company’s stock after acquiring an additional 3,183 shares during the period. Cwm LLC’s holdings in Perrigo were worth $298,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Central Pacific Bank Trust Division bought a new stake in Perrigo during the 1st quarter valued at approximately $48,000. Beach Investment Counsel Inc. PA acquired a new stake in shares of Perrigo in the second quarter worth $72,000. TFC Financial Management Inc. increased its position in Perrigo by 39.7% during the first quarter. TFC Financial Management Inc. now owns 2,462 shares of the company’s stock worth $79,000 after acquiring an additional 700 shares during the period. Voisard Asset Management Group Inc. boosted its holdings in Perrigo by 520.0% in the 2nd quarter. Voisard Asset Management Group Inc. now owns 4,650 shares of the company’s stock valued at $119,000 after purchasing an additional 3,900 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Perrigo in the 2nd quarter worth $213,000. 95.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PRGO shares. StockNews.com raised shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. Piper Sandler reduced their price objective on Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Canaccord Genuity Group restated a “buy” rating and set a $42.00 price objective on shares of Perrigo in a research report on Monday, September 30th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $30.00 target price (down from $50.00) on shares of Perrigo in a research report on Monday, September 23rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $37.00.

Perrigo Stock Up 2.2 %

NYSE PRGO opened at $25.85 on Tuesday. Perrigo Company plc has a 1-year low of $23.89 and a 1-year high of $34.60. The company has a market capitalization of $3.52 billion, a price-to-earnings ratio of -369.29 and a beta of 0.48. The stock’s 50 day moving average is $26.82 and its two-hundred day moving average is $27.97. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 0.80.

Perrigo (NYSE:PRGO) last announced its quarterly earnings results on Friday, August 2nd. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.46 by $0.07. Perrigo had a positive return on equity of 6.79% and a negative net margin of 2.81%. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the previous year, the firm earned $0.63 EPS. Perrigo’s quarterly revenue was down 10.7% on a year-over-year basis. Equities analysts forecast that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 17th. Shareholders of record on Friday, August 30th were given a $0.276 dividend. The ex-dividend date was Friday, August 30th. This represents a $1.10 dividend on an annualized basis and a yield of 4.27%. Perrigo’s dividend payout ratio (DPR) is presently -1,571.43%.

Insiders Place Their Bets

In other news, Director Katherine C. Doyle sold 8,954 shares of Perrigo stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $27.30, for a total value of $244,444.20. Following the completion of the transaction, the director now owns 6,009 shares in the company, valued at approximately $164,045.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Katherine C. Doyle sold 8,954 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $27.30, for a total value of $244,444.20. Following the completion of the sale, the director now directly owns 6,009 shares in the company, valued at approximately $164,045.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Ronald Craig Janish sold 13,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $29.40, for a total transaction of $382,200.00. Following the completion of the sale, the executive vice president now owns 20,553 shares of the company’s stock, valued at $604,258.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,254 shares of company stock valued at $1,411,969. 0.70% of the stock is currently owned by insiders.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.